What the hearing was about
The Senate HELP Committee hearing on September 24, 2024 — titled "Why Is Novo Nordisk Charging Americans with Diabetes and Obesity Outrageously High Prices for Ozempic and Wegovy?" — was the most direct congressional examination to date of GLP-1 pricing in the United States.
Senators focused on three points:
- U.S. list prices for Ozempic and Wegovy are several times higher than prices in Canada, Denmark, Germany, and the United Kingdom for the same medication from the same manufacturer.
- High prices push patients off treatment and add cost pressure to Medicare, Medicaid, and employer plans.
- Manufacturer arguments about R&D and rebates did not fully explain the gap between U.S. and international pricing.
Why this matters for patients
List price is not what most insured patients pay at the counter, but it drives what uninsured and cash-pay patients are charged and what insurance plans decide to cover. When list prices stay high, coverage rules get stricter and out-of-pocket costs stay unpredictable. That is a large reason patients turn to telehealth programs that publish flat, all-in pricing.
What has not changed
The hearing did not, on its own, force a price change. It put the pricing question formally on the congressional record and set the frame for follow-up hearings on the prescription drug supply chain in 2026.